$AXPBullishMed

American Express Card Spending Is Growing at Its Fastest Pace in 3 Years. Can the Affluent Consumer Keep It Up?

American Express reported first-quarter billed business of $428 billion, up 10% year over year, the fastest growth pace in three years, according to the company. Retail spending rose 11% and luxury retail 18%. The article notes 73% of new card accounts were for fee-paying products and net write-offs were 2% in Q1.

8/10
6/10
Med
Bullish
post-Q1 narrative; informs positioning ahead of next consumer/credit datapoints
supports a constructive view on affluent-consumer spending and credit quality

Faster billed-business growth and improving net write-offs support a more resilient consumer-spend thesis for AXP despite 2026 stock underperformance.

American Express billed business rose 10% YoY in Q1 to $428B, with luxury retail up 18% and premium card demand highlighted.

Near-term bias modestly positive as investors may re-rate AXP on stronger spend/credit quality signals.

Background

AXP is a spend- and fee-centric card issuer; the article contrasts 2026 stock weakness with Q1 billed-business acceleration and discusses inflation risk to cardholders.

Why it matters

If affluent retention and premium fee mix remain strong, AXP’s revenue outlook could look steadier even under higher inflation; improving net write-offs reduce downside risk from credit deterioration.

Market relevance

Traders can use the Q1 billed-business and credit-quality datapoints as inputs for near-term sentiment and risk assessment around consumer-spend resilience.

Market effects

Reinforces read-across for premium card issuers: affluent spend resilience and improving write-offs can offset inflation fears.

Primarily US consumer/credit conditions; no specific regional shock cited.

Limited—focus is on US card spending dynamics and macro inflation backdrop.

Alternative perspectives

Luxury and affluent spend growth may be less durable if inflation pressures broaden beyond premium cohorts, risking a deceleration after the current quarter.

The piece doesn’t quantify how billed-business growth translates into net revenue/earnings, nor does it address potential credit-cost normalization beyond the cited 2% write-off rate.

Key entities

  • American Express

    AXP reported Q1 billed business growth and highlighted premium card retention, luxury spend strength, and improved net write-off rate.

Related articles

$COFLow

Is Capital One Stock Underperforming the Dow?

Capital One said it is working through headwinds from Discover’s earlier credit policy cutbacks that have weighed on card growth. The company plans integration milestones for Discover and Brex, higher marketing and technology investment, and expansion of its digital-first banking and payments ecosystem. Analysts (23) still rate it a “Strong Buy,” with an average $255.54 price target, implying 43.9% upside.

$GSMed

Dow industrial average is surging led by financials in healthcare.

The Dow Jones Industrial Average rose about 930 points, or 1.84%, with 25 of 30 components higher and the index on pace for a record close. Financials led, including Goldman Sachs (+4.93%), JPMorgan (+3.64%) and American Express (+4.41%), while healthcare also supported gains such as UnitedHealth (+5.20%) and Merck (+3.73%). Decliners included Verizon (-2.44%) and IBM (-1.10%).

$AXPLow

Forget the "Magnificent Seven." This Financial Stock Could Be the Better Long-Term Bet.

The article argues that investors may look beyond the “Magnificent Seven” to American Express (AXP). It says American Express’ closed-loop model (payment network plus lending) and its premium cards are attracting younger consumers; millennials and Gen Z are described as the largest share of new card spending. Analysts expect ~14% annual earnings growth over 3–5 years, and the stock trades at about 18x 2026 earnings.

$AXPLow

Is American Express Stock Underperforming the S&P 500?

American Express shares have trailed the S&P 500, according to the article. Still, analysts are moderately optimistic: 29 analysts rate the stock a “Moderate Buy,” and the consensus mean price target is $362.23, about 14.5% above current levels. The piece notes the author held no positions in the mentioned securities.